BlackRock Health Sciences Term Trust Plans Monthly Dividend of $0.18 (NYSE:BMEZ)

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a monthly dividend on Friday, November 1st,NASDAQ Dividends reports. Shareholders of record on Friday, November 15th will be paid a dividend of 0.1769 per share on Friday, November 29th. This represents a $2.12 annualized dividend and a yield of 13.53%. The ex-dividend date of this dividend is Friday, November 15th.

BlackRock Health Sciences Term Trust has raised its dividend payment by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Performance

BMEZ traded down 0.15 during trading on Wednesday, hitting 15.69. The stock had a trading volume of 205,267 shares, compared to its average volume of 264,339. The company’s 50-day moving average price is 15.80 and its 200 day moving average price is 15.56. BlackRock Health Sciences Term Trust has a twelve month low of 13.41 and a twelve month high of 16.59.

Insiders Place Their Bets

In related news, major shareholder Saba Capital Management, L.P. bought 27,148 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of 15.93 per share, for a total transaction of 432,467.64. Following the transaction, the insider now owns 20,565,579 shares of the company’s stock, valued at approximately 327,609,673.47. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have purchased 99,630 shares of company stock worth $1,585,113.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.